Type of information: Collaboration agreement
Compound: MOSAIC (MOlecular Signatures of Adjuvanted vaccIne
Company: Bioaster (France) Sanofi Pasteur (France)
Therapeutic area: Infectious diseases
Type agreement: collaboration - research
Action mechanism: adjuvant
- • On January 8, 2018, Bioaster announced it has teamed up with Sanofi Pasteur to initiate a collaborative project aiming at improving the safety and immunogenicity of adjuvants included in the composition of new candidate vaccines. MOSAIC (MOlecular Signatures of Adjuvanted vaccIne Candidates) will study the molecular signature of the adjuvanted vaccine candidates within and across species. MOSAIC will rely on several pre-clinical experimental species and a dedicated clinical trial to decipher adjuvant mode of action. This project is a unique opportunity to bridge cellular and molecular adjuvant specific signatures across species in order to better define their predictive capacities for human vaccine development. The success of the project will rely on a robust bioinformatics infrastructure able to host massive omics data and the development of innovative approaches to achieve advanced multi-omics data integration.